Development and Preliminary Testing of a Decision aid to Support Hodgkin Lymphoma Survivors Considering Lung Cancer Screening

Rachel Broadbent (rachel.broadbent-2@postgrad.manchester.ac.uk)
Christie Hospital NHS Foundation Trust

Tania Seale
University of Manchester

Christopher J. Armitage
University of Manchester

Kim Linton
Manchester Cancer Research Center

Research Article

Keywords: Hodgkin lymphoma, Lung cancer screening, Decision aid

Posted Date: October 8th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-956153/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Decisions aids (DA) can support patients to make informed decisions about screening tests. This study describes the development and initial evaluation of a lung cancer screening (LCS) DA targeted towards survivors of Hodgkin lymphoma (HL).

Methods

A prototype decision aid booklet was developed and subsequently reviewed by a steering group who provided feedback. Revisions were made to produce the DA tested in this study. HL survivors were recruited to an online survey and/or focus groups. Lymphoma practitioners were invited to an interview study. In the online survey, decisional conflict scales and knowledge scales were completed before and after accessing the DA. The focus groups and interviews explored acceptability and comprehensibility and the decisional needs of stakeholders. Focus groups and interviews were audio recorded. The framework method was used to analyse qualitative data.

Results

38 HL survivors completed the online survey. Following exposure to the DA, knowledge of LCS and risk factors and decisional conflict scores (total score and subscale scores) improved significantly. 11 HL survivors took part in two focus groups (n=5 and n=6) and 11 practitioners were interviewed. Focus group and interview results: The language, format and length were considered acceptable. Both groups felt the DA was balanced and presented a choice. Icon arrays were felt to aid comprehension of absolute risk values and for some survivors, they reduced affective risk perceptions. Among survivors, the impact of radiation risk on decision making varied according to gender and screening interval, whilst practitioners did not anticipate it to be a major concern for patients. Both groups expressed that a screening offer could mitigate anxiety about lung cancer risk. As anticipated by practitioners, survivors expressed a desire to seek advice from their clinical team. Practitioners thought the DA would meet their informational needs regarding lung cancer screening when supporting survivors.

Conclusions

The DA tested in this study is considered acceptable by HL survivors and their practitioners. The DA reduces decisional conflict and improves knowledge in HL survivors, suggesting that it would support HL survivors to make informed decisions when considering lung cancer screening in a future clinical trial.

Background

People invited to undergo cancer screening must be provided with information to support informed decision making about participation, in keeping with the General Medical Council guidelines on decision making and consent.1 In the UK, guidance issued by NHS Cancer Screening Programmes stipulates that
screening programmes should provide patients with educational materials covering the purpose of the investigation, the risks, benefits and burdens of the screening test and the likelihood of the test outcomes.²

Decision aids are evidence-based tools which should support patients in their decision making when facing healthcare options and help patients to make explicit decisions in accordance with their personal values.³ An updated Cochrane systematic review examined the use of decision aids in people facing healthcare or screening decisions and found that compared to usual care, decision aids improve knowledge and accuracy of risk perception, increase value-based decision making and reduce decisional conflict related to feeling uninformed, thus improving the quality of decision making.³ A number of decision aids have been developed to support patients making decisions about cancer screening, including ever smokers considering lung cancer screening ⁴–⁶ and those with low literacy levels considering bowel cancer screening.⁷,⁸

Lung cancer screening has been implemented for ever smokers over the age of 55,⁹,¹⁰ but most Hodgkin lymphoma survivors who are at risk of developing lung cancer due the carcinogenic effects of thoracic radiotherapy and chemotherapy¹¹ will not be eligible for screening as the majority are non-smokers.¹² Clinical trials of lung cancer screening for Hodgkin lymphoma survivors are underway,¹³,¹⁴ but to our knowledge, educational materials to support decision making have not been developed. Existing lung cancer screening education materials are targeted towards ever smokers and are not appropriate for HL survivors as they do not address treatment related lung cancer risk. Prior research has found that HL survivors have a low perceived risk of lung cancer due to a lack of awareness of the risks associated with cancer treatment.¹⁵ There is a need to develop educational materials targeted towards HL survivors considering lung cancer screening to use in future trials and screening programmes. To address this, we have developed a decision aid for use in a future trial of lung cancer screening. This paper describes the development process and results of preliminary testing among patient and practitioner stakeholders.

**Methods**

**Development of the decision aid prototype**

The decision aid we have developed is intended for use in a future trial of lung cancer screening using low-dose CT scans in at risk HL survivors. The International Patient Decision Aids Standards instrument (IPDASi) was used to guide content development.¹⁶

**Content development**

Published literature informed the manner in which risk information is presented in the decision aid. Evidence has shown that presenting absolute risk values improves accuracy of risk perceptions compared to relative risk values ¹⁷–¹⁹ and there is a consensus in the literature that the absolute risk format is the optimal method for presenting risk data.²¹,²² Therefore, absolute risk values are presented in
the decision where possible, avoiding the use of relative risk, or numbers needed to screen. Where absolute risk information was not published, the Winton Centre for Risk and Evidence Communication Real Risk-Make Sense of Your Stats website\textsuperscript{23} was used to calculate absolute risk by extracting data from published literature. Absolute risk values are accompanied throughout the decision aid by visual aids in the form of icon arrays, which have been shown to improve accuracy and comprehension of risk perception.\textsuperscript{17,24} There are instances where risk is presented qualitatively in the decision aid: firstly, to describe the greater likelihood of lung cancer in HL survivors who have smoked and secondly in HL survivors with a family history of lung cancer. In these specific examples, published data did not provide absolute risk values (or the raw data required to calculate these independently). In the example of smoking history, absolute risk value calculated from the sole paper providing raw data was misleading in that it suggested that HL survivors who are never smokers do not develop lung cancer. Since the literature suggests that most HL survivors who develop lung cancer have a history of smoking, we used the statement “most people who get lung cancer after Hodgkin lymphoma have smoked” in the decision aid.

There is strong evidence from a Cochrane systematic review\textsuperscript{25} that personalised risk communication promotes informed uptake of screening tests and increases knowledge. Personalised risk information is provided in the decision aid with regards to absolute lung cancer risk by gender and the receipt of chemotherapy alone or chemotherapy and radiotherapy. In the absence of a lung cancer risk calculator for this population, it was not possible to provide individualised risk scores.

Published literature also informed the information in the decision aid regarding risk factors for developing lung cancer after treatment for Hodgkin lymphoma,\textsuperscript{11,26–28} cumulative incidences and absolute risk levels.\textsuperscript{27,29} Information about the lung cancer screening test was informed by publicly available information and an online lung cancer screening decision tool\textsuperscript{30,31} whilst the information on the likelihood of a pulmonary nodule being detected on screening was informed by retrospective data on prevalence of pulmonary nodules in Hodgkin lymphoma survivors undergoing chest CT.\textsuperscript{32} The Centre for Disease Communication ‘Everyday Words for Healthcare Communication’ booklet and online clear communication index tool guided the language used.\textsuperscript{33,34}

**Input of the steering group**

A steering group of clinical experts and patients was set up, comprising 9 individuals with expertise in lymphoma late effects, lung cancer screening, risk and cancer communication and 3 survivors of HL (2 female, 1 male). All members of the steering group provided feedback on an initial prototype draft – developed by RB - which was subsequently revised to produce the version for preliminary testing among stakeholders. The steering group later commented on RB’s proposed amendments to the decision aid following stakeholder testing in the ENGAGE-HL study, described below. These processes form part of a published model of development processes for decision aids.\textsuperscript{35}

**The decision aid prototype**
The decision aid prototype is a 16-page booklet, designed to be read in paper format, entitled ‘Screening to find the early signs of lung cancer after treatment for Hodgkin lymphoma: Helping you decide’. The features of the decision aid prototype are detailed in Table 1 in supplementary data, but the decision aid is not publicly available at present.

**Testing the decision aid among stakeholders: The ENGAGE-HL study**

A study using mixed quantitative and qualitative methodology was developed to test the decision aid among people treated for HL and practitioners. Mixed methodology was chosen to facilitate quantitative analysis of the impact of the decision aid using validated scales, whilst qualitative methods were used to explore the perspectives of stakeholders in depth.

The specific study objectives were:

1. To assess the acceptability and comprehensibility of the decision aid amongst HL survivors and practitioners
2. To explore the decisional needs of HL survivors and informational and support preferences with regards to a lung cancer screening invitation
3. To explore the needs of practitioners providing support to survivors making the decision.
4. To assess the impact of the decision aid on HL survivors’ knowledge about lung cancer risk and lung cancer screening and on decisional conflict

**Theoretical framework**

The Ottawa Decision Support Framework describes the interaction of decisional needs, decision quality and decision support and asserts that unresolved needs negatively impact decision quality, which can adversely impact emotions, behaviour and health outcomes. Decision support strategies can improve decision quality by addressing unresolved needs, which may include inadequate knowledge and unrealistic expectations. This framework and the ‘Decisional Needs in Populations’ workbook were used to develop the questionnaire items and topic guides for interviews and focus groups.

**Study design**

There are two parts to the study: Part A recruited HL survivors to an online survey and/or a focus group whilst in Part B recruited lymphoma practitioners to an interview study. HL survivors were eligible to participate if they were treated in the UK, were aged 18 or over and had not been diagnosed with lung cancer or participated in a lung cancer screening pilot. Practitioners were eligible if they worked in the UK in a clinical role treating or supporting HL patients.

**Recruitment**

To recruit HL survivors to part A, a study advert was placed on the Lymphoma Action charity Twitter feed on multiple occasions over a 4 week period and posted twice on the Lymphoma Action Facebook support
page. The study advert was also included in the Lymphoma Action magazine and in an email to Lymphoma Action members. The study advert directed interested individuals to contact the researchers or access the study website, which hosted the participant information sheet, researchers contact details, and a link to the online survey.

To recruit practitioners to Part B, a separate study advert was placed on the Lymphoma Action charity Twitter feed and further information was available on the Lymphoma Action website. Study details were also listed on the British Society for Haematology website. Practitioners were sent the participant information sheet by email. All participants (in both Part A and B) were offered a £30 e-voucher for their participation (if a HL survivor participated in the focus group and completed the online survey, they received two £30 vouchers).

**Part A study procedures**

Online survey:

Participants in part A completed an online consent form followed by a survey, hosted on the Qualtrics platform. The online survey captured demographic data and measured lung cancer screening knowledge and decisional conflict before and after the participant accessed a pdf version of the decision aid. Lung cancer screening knowledge was measured using a 16-item scale, adapted from a published scale,\(^{(38)}\) and decisional conflict was measured using the Low Literacy Decisional Conflict Scale (DCS).\(^{(39)}\) Additional novel questions explored aspects of decisional conflict, information and support preferences and acceptability of the decision aid. The Short Test Of Functional Health Literacy Assessment\(^{(40)}\) (S-TOFHLA) was administered at the end of the survey.

Focus groups:

Two focus groups, lasting 60 minutes, took place using Zoom teleconferencing and were audio recorded. Participants were required to complete an online consent form and short questionnaire to collect personal characteristics prior to the focus group and were sent a pdf version of the decision aid to view at least 48 hours prior to the focus group. The main researcher (RB) and a second moderator attended the focus groups.

**Part B study procedures**

Semi-structured interviews, lasting 25-45 minutes, took place over telephone or Zoom and were audio-recorded. Practitioners completed an online consent form prior to the interview. A topic guide covered questions relating to the decisional needs of HL survivors considering lung cancer screening, the comprehensibility and acceptability of the decision aid and practitioners’ lung cancer screening informational needs.

**Data analysis**

Online survey (Part A)
Participant characteristics and their responses to questions exploring decisional conflict and support and information preferences are presented descriptively. To compare the difference in median total DCS scores and subscale scores and median proportion of correct answers given in the knowledge scale before and after exposure to the decision aid, the Wilcoxon signed rank test was used as the data did not meet tests for normality. McNemars test was used to compare screening intention before and after exposure to the decision aid. A significance level of 0.05 was used throughout. Effect sizes are presented using Cohens \( d \) values, defined as small \( (d = 0.2) \), medium \( (d = 0.5) \), and large \( (d = 0.8) \). The percentage of correct answers given to each question or statement in the knowledge scale and the median DCS scores and interquartile ranges are also presented descriptively.

Focus groups with patients (Part A) and interviews with healthcare practitioners (Part B)

The focus groups and interview recordings were transcribed intelligent verbatim. Since the interview and focus group schedules covered similar topics, the framework method of content analysis was used with the aim of identifying concordant and contrasting views among HL survivors and practitioners. NVivo 12 software was used to store and organise transcript files, codes and the framework matrix. The first author applied codes to the interview and focus group transcripts independently, producing two sets of codes, one for the interviews and one for the focus groups. This was an iterative process whereby codes were applied to the transcripts of the first seven interviews and the first focus group, and when the remaining interviews were transcribed and the second focus group had taken place, a further round of coding took place where previously developed codes, and new codes, were applied. Two researchers (RB and TS) met to discuss the codes and emerging themes, at which point any disagreements over coding were resolved. Subsequently, RB developed a coding framework which could be applied to both focus group and interview transcripts. During the development of the thematic analysis, the RB and TS met on multiple occasions to discuss the emerging themes. The results of the study have been made available on the study website (engagehl.com). But participants have not been involved in the analytic process.

Reflexivity statement

Focus group participants and practitioners were aware that the interviewer (RB) had been involved in developing the decision aid that they were reviewing. Being aware of this, the interviewer took care to facilitate a safe environment in which participants could openly express their views towards the decision aid - including negative ones – by encouraging participants to share both positive and negative views and seeking their views throughout of ways to improve it. The interviewer was willing to answer questions that participants had on the topic of lung cancer screening and to discuss the rationale behind decisions that had been made during the development of the decision aid.

During the second focus group, the researcher (RB) explored issues which had not been addressed in the first focus group or which merited further exploration and additionally explored issues that had emerged from an interim analysis of the online survey. Thus, the questions posed to the second focus group were influenced by the preceding research activities. During the coding and development of the themes, two
researchers discussed the challenges associated with running the focus groups, including group dynamics. They acknowledged the potential for their experience of running the focus groups to influence the resulting codes and themes, and efforts were made to remain unbiased in the weight attributed to the views of individual participants when developing the thematic analysis.

Results

Part A

The online survey was completed by 38 HL survivors described in Table 1. In summary, the majority were female with a median age of 44, of white British ethnicity and were never smokers. There was a wide range of time since follow-up among participants and slightly more remained in follow-up than were discharged. All participants had adequate levels of health literacy according to S-TOFHLA.
Table 1
Personal characteristics of participants

| **HL survivors**          | Focus group 1: n=6 | Focus group 2: n=5 |
|---------------------------|---------------------|---------------------|
| **Online survey: participants personal characteristics n=38** |                      |                      |
| **Gender**                | Female: 30          | Female: 3           |
|                           | Male: 8             | Male: 3             |
| **Median age (range)**    | 44 (21-71)          | (26-60)             |
|                           | (21-71)             | (21-71)             |
| **Ethnicity**             | White British: 30   | 5 white British,    |
|                           | Other white background: 4 (1 Spanish, 1 Portuguese, 1 Polish, 1 not stated) | 1 Spanish          |
|                           | Indian: 1           | All white British   |
|                           | Pakistani: 1        |                     |
|                           | Irish: 1            |                     |
| **Smoking status**        | Never smoker: 25    | Not captured        |
|                           | Ex-smoker: 12       | Not captured        |
|                           | Current smoker: 1   |                     |
| **Years since HL treatment:** | <5: 17              | <5 years: 4         |
|                           | 5-10: 6             | 5-10 years: 2       |
|                           | 11-15: 3            | 5-10 years: 2       |
|                           | 16-20: 1            | >20 years: 2        |
|                           | >20 years: 11       |                     |
| **Follow-up status**      | 21 remain in follow-up | 4/6 remain in follow-up | 3/5 remain in follow-up |
|                           | 17 discharged from follow-up |                      |                      |
| **Treatment for HL**      | Not captured        | All received        |
|                           |                     | chemotherapy alone  |
|                           |                     | Radiotherapy only: 1|
|                           |                     | Chemotherapy only: 2|
|                           |                     | Both: 2             |
| **Level of education completed** | Not captured        | 2: GCSE/O-level     |
|                           |                     | 1: A-levels         |
|                           |                     | 3: university educated|
|                           |                     | 2: A-levels/other college education |
|                           |                     | 3: university educated|
| Role (number) | Consultant haematologist (3) |
|--------------|-----------------------------|
|              | Senior registrar (doctor) (1) |
|              | Advanced nurse practitioners (haematology/lymphoma) (3) |
|              | Clinical nurse specialist in lymphoma (4) |

**Lung cancer risk and screening related knowledge:**

The median percentage of correct responses to knowledge questions and statements increased following exposure to the decision aid (68% pre exposure, 93% post exposure (p value <0.001). The effect size was 1.4. The percentage of correct answers given to each question pre and post exposure to the decision aid is shown in the Supplementary data file (Table 2)

**Decisional conflict:**

In the decisional conflict scale and subscales, higher scores represent higher levels of decisional conflict, higher levels of uncertainty, feeling more uninformed, feeling more unsupported and feeling more unclear about personal values. Following exposure to the decision aid, median total DCS scores and median uncertainty, informed, values clarity and support subscale scores reduced indicating that the decision aid reduced levels of decisional conflict, reduced uncertainty, increased feeling of being informed, increased values clarity and feelings of being supported. Median scores, range, interquartile range, p-values for difference in pre-post median scores and effect size shown in Table 2.
Table 2

Decisional conflict median scores pre and post exposure to the decision aid.

|                      | Pre: Median (range; interquartile range (IQR)) | Post: Median (range; interquartile range) | p value for difference in median pre and post scores | Effect size (Cohens d value) |
|----------------------|-----------------------------------------------|------------------------------------------|-----------------------------------------------------|-----------------------------|
| Total DCS score      | 67.5 (0-100; IQR 40)                         | 0 (0-80; 10) p<0.001                     | 1.9                                                 |
| Uncertainty subscale | 50 (0-100; IQR 80)                           | 0 (0-100; IQR 6.25) p<0.001              | 1.0                                                 |
| Informed subscale    | 100 (0-100; IQR 37.51)                       | 0 (0-66; IQR 0) p<0.001                  | 2.0                                                 |
| Values clarity subscale | 75 (0-100; IQR 56.25)             | 0 (0-100; IQR 0) p<0.001                  | 1.5                                                 |
| Support subscale     | 33.33 (0-100; IQR 41.67)                     | 0 (0-100; IQR 0) p<0.001                  | 0.7                                                 |

Intention to participate in a future lung cancer screening programme

Before and after accessing the decision aid, participants were asked: “If you were invited to go for a lung cancer screening test, would you go?” Prior to reading the decision aid, 33 (86.84%) participants responded ‘Yes, definitely’ and 5 (13.15%) responded ‘Yes, probably’. After reading the decision aid, 29 (76.31%) responded ‘Yes, definitely’ and 9 (23.68%) responded ‘Yes, probably’. The difference in strength of intention before and after reading the decision aid was not significant (p=0.21).

Decision making and information and support preferences

Participants answered the following questions before accessing the decision aid. Responses to the question, ‘If you were invited to lung cancer screening, how easy would it be for you to make the decision?’ were as follows: ‘extremely easy’ or ‘quite easy’: 65%, ‘neither easy nor difficult’: 26%, ‘quite difficult’: 7%. Participants rated their level of agreement to a series of questions assessing difficulties relating to decision making. The results are shown in Table 3.
Table 3
Responses to questions regarding difficulties in decision making

| Statement                                              | Response (%)          |
|--------------------------------------------------------|-----------------------|
|                                                        | Strongly disagree /   |
|                                                        | Disagree              |
|                                                        | Neither agree nor     |
|                                                        | disagree              |
|                                                        | Strongly agree /      |
|                                                        | agree                 |
| I would be unsure what to do                           | 65.78                 |
|                                                        | 13.15                 |
|                                                        | 21.05                 |
| I would be worried what could go wrong                  | 54.94                 |
|                                                        | 23.68                 |
|                                                        | 21.05                 |
| Trying to make the decision would upset me             | 81.57                 |
|                                                        | 7.89                  |
|                                                        | 10.25                 |
| I would be constantly thinking about the decision      | 89.47                 |
|                                                        | 7.89                  |
|                                                        | 2.63                  |

After reading the decision aid, 60.6% said they would not seek out more information, 34% would and 5.2% were unsure. Participants were asked to select the support options might be useful to them. Responses were as follows: searching the internet: 65.8%, charity or organisation webpage: 76.3%, talking to a doctor or specialist nurse: 73.7%, asking a support group: 13.1%.

Nineteen respondents (50%) said they would involve someone else in their decision making and all those responding this way indicated they would involve their family in the decision whilst 2 (5.3%) said they would involve their clinical team. When asked about the level of involvement of the doctor in decision making, 52.6% said they would decide on their own, 34.2% said they would decide after considering their doctor’s opinion, 10.5% would decide with their doctor, and 2.6% said their doctor would decide after considering their opinion.

Acceptability of the decision aid prototype

86.6% said the length was ‘just right’, whilst 13.2% said it was ‘too long’. 94.7% said the amount of information in the decision aid was ‘just right’ whilst 5.3% said it was ‘too much’. Participants were asked to rate the way the information was presented within the different sections of the booklet. Their responses are shown in Table 4. Asked about the balance of the information, 76.3% said it was balanced, 21% said it was ‘slanted towards having a lung cancer screening test’ and 2.6% said it was ‘slanted towards not having a lung cancer screening test’. All participants said they would find the decision aid useful if they had to make a decision about undergoing lung cancer screening.
Table 4  
Ratings given to sections of the decision aid

| Section of the decision aid                                           | Response (%) |
|-----------------------------------------------------------------------|--------------|
|                                                                       | Excellent/good | Fair/Poor   |
| How likely is it that I will develop lung cancer?                      | 81.57        | 18.41       |
| What does lung cancer screening involve?                               | 97.36        | 2.63        |
| What are the benefits of having a lung cancer screening test?          | 97.36        | 2.63        |
| What are the disadvantages of having a lung cancer screening test?     | 94.73        | 5.26        |
| Making a decision                                                     | 81.57        | 18.42       |
| What are the symptoms of lung cancer?                                 | 89.47        | 10.52       |
| Information and Support                                               | 94.72        | 5.26        |

Thematic analysis of focus groups with HL survivors and interviews with practitioners

Theme 1: Accessing and understanding the decision aid document

Acceptability

During the focus group, participants’ perspectives on the language, length and format were explored, with probing questions to generate a deeper understanding of viewpoints. All groups agreed that the language was clear and jargon-free, especially by focus group participants experienced in patient and public involvement and engagement (PPIE). The length of the decision aid (16 pages) was a cause for concern, however as information was felt to be “concise” and the layout “uncluttered” the length was generally considered manageable:

“Because it’s written so clearly and in such simple language once you start reading it it’s actually a lot quicker than you think” (Focus group 2 participant, female)

Linked to this, participants felt strongly that the decision aid document should be comprehensive despite its length and it was pointed out that recipients could “dip in and out of it”. Across the two focus groups, suggestions were made to improve the readability through simple format changes, such as the use of bullet points and bold headings. It was suggested that videos or forums may be a better source of information and support for patients less likely to read written information.
Comprehension of lung cancer risk information

During the focus groups, it emerged that participants had become aware of the treatment-related risk of lung cancer for the first time through participation in this study and had therefore not been previously exposed to data relating to this risk. This lack of prior awareness impacted their perceptions of the absolute risk values that were presented in the decision aid. Those who perceived the values to be lower than they had anticipated gleaned some reassurance, but this was not universal. A female focus group participant who was treated at a young age said she had not expected to get lung cancer, so the values still appeared “quite high”. In relation to this, it appeared that using icon arrays to support textual information on absolute risk aided comprehension and reduced affective risk perceptions.

“With regards to it being simple for others to read, I definitely found the graphics useful from that perspective just to get a real insight. You can say four in 100 people, but when you see it in an infographic it’s much more impressionable I guess, and you relax a bit more and your anxiety leaves, that actually the chances are that’s probably not me.” (Focus group 1 participant, female)

Practitioners also viewed the icon arrays positively, saying they were a simple but effective method of communicating risk.

Practitioners felt it was important for recipients of the decision aid to be able to identify the treatment related risk factors relevant to them. In keeping with this, there were multiple occasions when focus group participants correctly identified their personal risk factors using the information in the decision aid. When participants could not see their chemotherapy regimen listed as a risk factor, they sought clarification from the researcher running the focus group.

Whilst the decision aid provided information on risk factors and the absolute risks relating to single and combined modality treatments, it was not tailored to individual recipients. One participant expressed concerns about this, saying that the information was not sufficient for her to understand her personal risk factors.

“I think it certainly doesn’t answer all the questions that I would have as to why I would be at risk personally. But you’re never going to cover that off, that’s the problem, in a leaflet. So, I think it does a good job of being quite generic and covering off the main reasons, without being specific; you’d have to reach out elsewhere.” (Focus group 1 participant, female)

Both practitioners and focus group participants raised concerns that the inclusion of lifetime cumulative lung cancer risk values for the general population (7-8/100) was confusing. They felt that these data contradicted the text which stated that HL survivors were at higher risk than the average person, because the lung cancer absolute risk value for HL survivors 35 years after treatment was 4-5/100, seemingly less than the general population. Practitioners widely recommended that alternative data be used.

Facilitating informed decision making
Across both focus groups, participants felt that the decision aid presented lung cancer screening as a choice rather than a recommendation. It was widely agreed among practitioners and focus group participants that presenting pros and cons in textual and summary table format would help facilitate informed decision making by helping people identify the issues that were most salient to them. Being able to weigh up pros and cons during decision making held more importance for some focus group participants than others, for example one participant who perceived a prior lack of involvement in decision making relating to her cancer diagnosis, said:

“I think that’s so important, especially when some of those decisions are taken completely out of your hands when you’re diagnosed with cancer.” (Focus group 1 participant, female)

In contrast, another participant indicated that the risks associated with screening were of minimal importance to them if there was any potential benefit: “If I know it’s going to help or it’s going to try and help us I’ll just do it.” (Focus group 1 participant, male)

Participants in the second focus group were asked to consider whether the decision aid was slanted towards lung cancer screening, which had been reported in the online survey analysis. There was agreement among them that the document was balanced and that the pros and cons of screening were described in equal detail. One participant wondered whether it was biased to present pros before cons but felt this was the “right decision” as presenting cons first may dissuade people from reading about the potential benefits.

**Theme 2: Factors influencing lung cancer screening participation decisions**

**Perceptions of radiation risk associated with lung cancer screening**

Participants were asked to consider the amount of information contained in the decision aid on the radiation risk associated with lung cancer screening. In the ensuing discussion, it emerged that the extent to which focus group participants were concerned about the radiation risk associated with screening was variable. In discussion this, two male participants agreed that although radiation could have adverse consequences, this knowledge would not prevent them from accepting a lung cancer screening test due to the potential benefits associated with early detection.

Another male participant said that whilst he placed more importance on radiation risk now that he was in remission, it remained a minor concern in view of previous cancer treatment:

“I guess from a fact point of view you can bombard me with anything else. You sign a form and bags of stuff arrive that say deadly on them with a skull and cross bone.” (Focus group 1 participant, male)
Conversely, one female participant said that as a young adult, her level of concern about radiation risk would be greater if regular screening was recommended over a long time period, whereas she would not be concerned about a single scan. For another female participant, the differing impact of radiation of men and women was an important consideration, for example in relation to fertility. In general, practitioners perceived that radiation risk would be a minor concern for patients in view of having undergone multiple scans:

“When you think of all the scans our patients have, it’s nothing really, is it?” (Clinical nurse practitioner)

A screening offer can provide a degree of reassurance about lung cancer risk

Health-related anxieties experienced by HL survivors, particularly regarding cancer recurrence but also about developing late effects of treatment, were discussed by both focus group participants and practitioners. Practitioners felt that anxiety and “hypervigilance” about their health would lead most survivors to take up an offer of lung cancer screening, making the decision a straightforward one.

“I think some people would bite your hand off to go and reassure themselves there’s nothing wrong” (Advanced nurse practitioner)

Additionally, practitioners felt that although an offer of lung cancer screening could exacerbate anxiety, survivors could be reassured by a screening offer. In considering this, they cited their experience of patients’ enthusiasm for surveillance imaging during follow-up. Focus group participants and practitioners went on to discuss the delivery of information about lung cancer risk. Both groups felt that delivering information about lung cancer risk in the context of an invitation to screening - accompanied by an explanation about the rationale - might somewhat mitigate the anxiety associated with becoming aware of this risk, although it was also said that reassurance could be short lived if regular screening were not available. Both groups noted that information on risk of late effects was often given without an offer or surveillance or screening.

“I'd find this arriving kind of reassuring cause it means someone's actually monitoring, checking up on you and not just leaving you to your own devices afterwards so you guys have assessed the risk and doing something about it which we don't get very much to be honest its more just, 'oh there's a risk' and they leave us alone.” (Focus group 2 participant, female)

**Patient age at approach about lung cancer screening**

Practitioners were asked about the challenges survivors might face when considering undergoing lung cancer screening. The age at which patients were approached about lung cancer screening was felt to be an important consideration. Practitioners felt that younger patients’ desire to “move on” from their illness might render them less likely to engage with information about late effects and screening. In contrast, they felt that people contacted about lung cancer screening at an older age would have better “emotional
capacity” to understand late effects information and engage with screening because they or their peers may be experiencing health problems, making health a more salient issue and higher priority.

In contrast with this, a focus group participant who was treated in their sixties and currently aged over 70 said that being treated at an older age led them to feel less concerned about lung cancer as a late effect, as they were not sure they would live long enough to be affected.

Although the desire to avoid “remedicalisation” could reduce engagement with screening in all age groups, practitioners thought this may be particularly relevant to people diagnosed at a young age:

“I think there will be some who will have a real issue with that identity of being someone who's still...who can possibly still get ill from something serious again in the future” (Lymphoma doctor)

**Theme 3: Information provision and support**

**Lung cancer screening discussions: past and future practice**

There was a perception among practitioners that although late effects had not been widely discussed with patients in the past, this had improved in recent years. Nevertheless, there was evidence of variation in current follow-up strategies and timing of discussions about late effects and screening opportunities, which one practitioner attributed to a lack of guidance.

“I don't think we have clear enough guidance that we can use uniformly across our Hodgkin lymphoma survivors and that's tailored to each patient as well.” (Consultant haematologist)

This was reflected in the focus groups, where participants described varied experiences of follow-up care and management of late effects. Participants appeared uncertain about how to access support around late effects and the one participant who had accessed a late effects clinic had done it through “self-advocacy”. Practitioners felt that if LCS were to become established in future, HL patients should be “forewarned” about future screening invitations whilst still in follow-up to mitigate the shock they might experience on receiving an invitation years later. Although practitioners did not offer a consensus as to the optimal time to deliver lung cancer screening information during the follow-up period, some perceived that patients would not be receptive to this screening information until they had achieved remission, as they would be focussed on getting through treatment.

“Screening would be something I would definitely want to talk about at the end of treatment rather than right at the beginning when they’ve already got those additional stresses.” (Consultant haematologist)

**Sources of information and support for HL survivors and their practitioners**
When discussing support and information, practitioners anticipated that HL survivors would prefer to access support and advice through their own clinical team with whom they had established a relationship and would be likely to follow the recommendation of their lymphoma physician, whose view they would “trust”. Indeed, focus group participants expressed their desire to seek advice from their clinical team and it appeared that a positive screening recommendation could be influential.

“If my consultant says to me take it, okay I’ll be there in five minutes, that’s my attitude.” (FG1, male)

Practitioners acknowledged that patients long discharged from follow-up may not have an obvious point of contact, in which case they might seek support from a variety of other sources including a designated nurse specialist for their local area, their GP, or patient charities. Family members were considered to be important and influential sources of support during decision-making.

Practitioners were asked how they might be informed and supported should lung cancer screening become available for their patients in future. Clinical nurse specialists said that having access to the same decision aid document given to patients would fulfil their informational needs, whilst some doctors felt more detail on risk stratification would be useful for them to discuss risk with patients. Nurse specialists did not anticipate difficulties in providing psychological support to patients, saying that this was a key part of their role.

**Discussion**

This paper describes the systematic approach to developing a decision aid and shows that the decision aid significantly improved lung cancer risk and screening related knowledge and reduced decisional conflict among HL survivors. Although the decision aid improved participants’ knowledge on treatment related lung cancer risk factors, the degree of improvement varied. For example, most participants were already aware of the lung cancer risk associated with radiotherapy, but far fewer had prior knowledge of the risk associated with chemotherapy. This may reflect the nature of information previously provided to participants about lung and other second cancer risks associated with radiotherapy. Nevertheless, it can be argued that even modest improvements in knowledge are of value because an improvement in knowledge around options and outcomes improves decision quality. Decisional conflict scores reduced after accessing the decision aid across all subscales but the smallest change in pre-post median scores and the smallest effect size was seen in the ‘support sub-scale’, possibly reflecting the fact that more than half of participants remained in follow-up, retaining access to their clinical team for advice.

Participants in the online survey universally expressed willingness to undergo lung cancer screening if invited, even before accessing the decision aid. The utility of a decision aid in a population who are already highly swayed towards one option – screening - could be questioned, but it can be argued that recipients who strongly favour an option at the outset would benefit from feeling better informed, supported and clearer in their values, thus improving the quality of the decision-making process and quality of the choice made. Notably, after accessing the decision aid, a higher proportion responded
that they would ‘probably’ attend lung cancer screening, as opposed to ‘definitely’. The improvement in decisional conflict scores after viewing the decision aid would suggest that this change in strength of intention could be a result of participants being more informed of their level of lung cancer risk and of the risks of screening, as opposed to feeling less certain about the decision they would make. Although not statistically significant, this finding highlights that becoming more informed can move screening intentions in both directions. This was demonstrated in the aforementioned Cochrane review of decision aids for people facing screening decisions, where there were mixed results in terms of uptake of breast and colorectal cancer screening after exposure to a decision aid.³

**Strengths and limitations**

A systematic process was followed in the development and testing of this decision aid as outlined in the literature³⁵ with involvement of patient and practitioner stakeholders at all levels of development and testing. The use of mixed methodology allowed us to quantify the impact of the decision aid through validated scales and to explore the perspectives of stakeholders and the issues pertinent to patients when facing lung cancer screening decision through qualitative methods. The framework method of analysis allowed us to identify areas of concordance and discordance between patients and practitioners. For transparency and rigour, we have reported the evaluation of the decision aid according to the Standards for UNiversal reporting of patient Decision Aid Evaluation (SUNDAE) checklist⁴⁵ although not all checklist items were relevant in this early phase of testing. A limitation of this study was the convenience method of sampling of HL survivors, which in turn limits the extent to which the decision aid can be considered acceptable and comprehensible to the wider population of HL survivors. We did not stipulate that patient participants received treatments that increased their lung cancer risk since this would require accurate recall of chemotherapy drugs and radiation site. Therefore, some participants were not at excess risk of lung cancer, meaning not all participants were representative of the intended target group for the decision aid. Nevertheless, a majority were considered to be at excess risk because of treatment trends in the last 40 years – this was the case for the focus groups where participants volunteered their treatment details – and the views of those who were not remain pertinent and relevant to our research questions. A further limitation of the convenience sampling strategy was that men, current smokers and non-white ethnicities were poorly represented among the patient participants meaning decisional needs unique to these groups would not have been identified. Finally, health literacy levels were high among survey participants and more than half of focus group participants were university educated. Given that 42% of working-age adults in the UK cannot understand everyday healthcare information, rising to 61% when numeracy is required for comprehension,⁴⁶ recipients of the decision aid within a future study may be less able to understand the decision aid than our participants.

**Conclusion**
The findings of this study suggest that the decision aid developed here would support informed decision making when provided to HL survivors considering undergoing lung cancer screening. Its’ suitability for use in a larger population who are more diverse in terms of ethnicity and educational level is uncertain and further research is warranted in those groups. Informed by the results of this study, the decision aid prototype tested here has been developed further by the steering group to produce a decision aid document which will be used in a future feasibility study of lung cancer screening in HL patients.47

**Abbreviations**

DA : decision aid  
HL: Hodgkin lymphoma  
LCS: lung cancer screening  
IPDASi: International Patient Decision Aid Standards instrument  
DCS: decisional conflict scale  
S-TOFHLA: Short Test of Functional Health Literacy Assessment  
SUNDAE: Standards for UNiversal reporting of patient Decision Aid Evaluation

**Declarations**

**Ethics approval and consent to participate:**

This study received ethical approval from The University of Manchester proportionate research ethics committee on 21st January 2021 (ref: 2021-10619-17592). All study procedures were performed in accordance with The University of Manchester research guidelines. Participation was voluntary and all participants provided electronic written consent.

**Consent for publication:**

Not applicable

Availability of data: all data generated or analysed during this study are included in this published article and its’ supplementary information files.

**Competing interests:**
The authors declare that they have no competing interests

**Funding:**

This study was funded by the Christie Charity, the NIHR Greater Manchester Patient Safety Translational Research Centre and the NIHR Manchester Biomedical Research Centre.

None of the funding bodies had input into the research described in this paper.

**Author contributions:**

RB undertook data collection, data analysis and wrote the manuscript. TS undertook data analysis. All authors approved the final manuscript.

**Acknowledgements**

We would like to acknowledge the members of the steering group for bringing their expertise and experience to this project.

Steering group members:

Dr Sally Taylor: researcher with expertise in patient-reported outcomes in oncology

Professor Diana Greenfield: professor of nursing with expertise in lymphoma late effects

Dr Philip Crosbie: respiratory physician with expertise in lung cancer screening

Dr Chris Keyworth: researcher with expertise in risk communication strategies

Anne Hook: publications manager at Lymphoma Action with expertise in patient directed publications

Tracy Howe: Lymphoma clinical nurse specialist, experienced in communicating with lymphoma patients

Dave Broadhurst: patient representative

Vicky Lee: patient representative

Gill Allan: patient representative

We thank the Lymphoma Action charity for their assistance in promoting the study. Rachel Broadbent and Christopher J Armitage are supported by the NIHR Manchester Biomedical Research Centre and the NIHR Greater Manchester Patient Safety Translational Research Centre. Rachel Broadbent is also supported by the Christie Charity. Tania Seale is supported by the Roy Castle Lung Cancer Foundation.
The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Authors information:

Dr Rachel Broadbent is a doctor training in medical oncology. She is undertaking PhD at The University of Manchester with the aim of investigating the feasibility of a lung cancer screening programme for survivors of Hodgkin lymphoma.

References

1. General Medical Council. Decision making and consent. 2020.
2. NHS Cancer Screening Programmes. Consent to Cancer Screening. Sheffield; 2009.
3. Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;2017(4). doi:10.1002/14651858.CD001431.pub5
4. Dharod A, Bellinger C, Case LD, Miller D. The Reach and Feasibility of an Interactive Lung Cancer Screening Decision Aid Delivered by Patient Portal. Appl Clin Inf. 2019;10:19–27.
5. Lowenstein LM, Escoto KH, Leal VB, et al. Randomized trial of a patient-centered decision aid for promoting informed decisions about lung cancer screening: Implementation of a PCORI study protocol and lessons learned. Contemp Clin Trials. 2018;72(July):26–34. doi:10.1016/j.cct.2018.07.007
6. Volk RJ, Lowenstein LM, Leal VB, Escoto KH, Cantor SB, Munden RF. Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke A Randomized Clinical Trial. JAMA Netw. 2020;3(1):1–12. doi:10.1001/jamanetworkopen.2019.20362
7. Smith SK, Trevena L, Barratt A, et al. Development and preliminary evaluation of a bowel cancer screening decision aid for adults with lower literacy. Patient Educ Couns. 2009;75:358–367. doi:10.1016/j.pec.2009.01.012
8. Smith SK, Trevena L, Simpson JM, Barratt A, Nutbeam D, Mccaffery KJ. A decision aid to support informed choices about bowel cancer screening among adults with low education: randomised controlled trial. 2010:1–13. doi:10.1136/bmj.c5370
9. NHS England - National Cancer Programme. Targeted Screening for Lung Cancer with Low Radiation Dose Computed Tomography Standard Protocol prepared for the Targeted Lung Health Checks Programme. https://www.england.nhs.uk/publication/targeted-screening-for-lung-cancer/. Published 2019. Accessed July 29, 2019.
10. U.S. Preventive Services Taskforce. Lung Cancer: Screening. 2021. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening.
11. Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. N Engl J Med. 2015;373(26):2499–2511.
12. Ng AK, Li S, Recklitis C, et al. Health Practice in Long-Term Survivors of Hodgkin’s Lymphoma. *Int J Radiat Oncol Biol Phys*. 2008;71(2):468–476. doi:10.1016/j.ijrobp.2007.09.028

13. Hodgson DC. Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease. https://clinicaltrials.gov/ct2/show/NCT00601146. Published 2018. Accessed July 9, 2019.

14. Ng AK. Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease. http://clinicaltrials.gov/ct2/show/NCT00601146.

15. Broadbent R, Seale T, Armitage CJ, Linton K. The perspectives of survivors of Hodgkin lymphoma on lung cancer screening: A qualitative study (In press). *Heal Expect*. 2021.

16. Elwyn G, O’Connor AM, Bennett C, et al. Assessing the quality of decision support technologies using the International Patient Decision Aid Standards instrument (IPDASi). *PLoS One*. 2009;4(3). doi:10.1371/journal.pone.0004705

17. Zipkin DA, Umscheid CA, Keating NL, et al. Evidence-based risk communication: A systematic review. *Ann Intern Med*. 2014;161(4):270–280. doi:10.7326/M14-0295

18. Covey J. A meta-analysis of the effects of presenting treatment benefits in different formats. *Med Decis Mak*. 2007;27(5):638–654. doi:10.1177/0272989X07306783

19. Edwards A, Elwyn G, Covey J, Matthews E, Pill R. Presenting risk information—a review of the effects of “framing” and other manipulations on patient outcomes. *J Health Commun*. 2001;6(1):61–82. doi:10.1080/10810730150501413

20. Moxey A, Dip G, Sci HS, Connell DO, Mcgettigan P, Henry D. How They Are Expressed Makes a Difference. 2002.

21. Gigerenzer G, Gaissmaier W, Kurz-Milcke E, Schwartz LM, Woloshin S. Helping doctors and patients make sense of health statistics. *Psychol Sci Public Interes Suppl*. 2007;8(2):53–96. doi:10.1111/j.1539-6053.2008.00033.x

22. Fagerlin A, Zikmund-Fisher BJ, Ubel PA. Helping patients decide: Ten steps to better risk communication. *J Natl Cancer Inst*. 2011;103(19):1436–1443. doi:10.1093/jnci/djr318

23. Winton Centre for Risk and Evidence Communication (University of Cambridge). Real Risk make sense of your stats. https://realrisk.wintoncentre.uk/. Accessed May 4, 2021.

24. Fraenkel L, Haven N, Peters E, et al. Shared Medical Decision Making in Lung Cancer Screening: Experienced vs. Descriptive Risk Formats. 2016;36(4):518–525. doi:10.1177/0272989X15611083.Shared

25. Edwards AG, Naik G, Ahmed H, et al. Personalised risk communication for informed decision making about taking screening tests. *Cochrane Database Syst Rev*. February 2013. doi:10.1002/14651858.CD001865.pub3

26. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. *J Natl Cancer Inst*. 2002;94(3):182–192.
27. Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. *J Clin Oncol.* 2011;29(31):4096–4104. doi:10.1200/JCO.2011.34.8268

28. Sud A, Thomsen H, Sundquist K, Houlston RS, Hemminki K. Risk of second cancer in Hodgkin lymphoma survivors and influence of family history. *J Clin Oncol.* 2017;35(14):1584–1590. doi:10.1200/JCO.2016.70.9709

29. Bright CJ, Reulen RC, Winter DL, et al. Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study. *Lancet Oncol.* 2019;20(4):531–545. doi:10.1016/S1470-2045(18)30903-3

30. Manchester University NHS Foundation Trust. About the lung health check - FAQs. https://mft.nhs.uk/lunghealthcheck/about-the-lung-health-check/faqs/. Accessed May 4, 2021.

31. Lau YK, Caverly TJ, Cao P, et al. Evaluation of a Personalized, Web-Based Decision Aid for Lung Cancer Screening. *Am J Prev Med.* 2015;49(6):e125-e129. doi:10.1016/j.amepre.2015.07.027

32. Broadbent R, Tenant S, Elshafei M, Radford J. The prevalence and characterisation of lung nodules in Hodgkin lymphoma survivors: a study to inform a future lung cancer screening programme. In: *NCRI Cancer Conference.* 2020.

33. Centres for disease control and prevention. The CDC Clear Communication Index. https://www.cdc.gov/ccindex/tool/index.html. Published 2020. Accessed May 4, 2021.

34. Centres for disease control and prevention. Everyday Words for Public Health Communication. May 2016. https://www.cdc.gov/other/pdf/everydaywordsforpublichealthcommunication.pdf. Accessed May 4, 2021.

35. Coulter A, Stilwell D, Kryworuchko J, Mullen PD, Ng CJ. A systematic development process for patient decision aids. *BMC Med Inform Decis Mak.* 2013;13(Suppl 2):S2. doi:10.1186/1472-6947-13-S2-S2

36. Stacey D, Légaré F, Boland L, et al. 20th Anniversary Ottawa Decision Support Framework: Part 3 Overview of Systematic Reviews and Updated Framework. *Med Decis Mak.* 2020;40(3):379–398. doi:10.1177/0272989X20911870

37. Jacobsen MJ, O'Connor AM, Stacey D. Decisional Needs Assessment in Populations. https://decisionaid.ohri.ca/docs/implement/Population_Needs.pdf. Published 2013. Accessed May 4, 2021.

38. Lowenstein LM, Richards VF, Leal VB, et al. A brief measure of Smokers’ knowledge of lung cancer screening with low-dose computed tomography. *Prev Med Reports.* 2016;4:351–356. doi:10.1016/j.pmedr.2016.07.008

39. O'Connor A. User Manual - Decisional Conflict Scale. https://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Decisional_Conflict.pdf. Published 2010. Accessed May 4, 2021.
40. Baker DW, Williams M V., Parker RM, Gazmararian JA, Nurss J. Development of a brief test to measure functional health literacy. *Patient Educ Couns.* 1999;38:33–42. doi:10.1016/S0738-3991(98)00116-5

41. Cohen J. *Statistical Power Analysis for the Behavioral Sciences.* New York, NY: Routledge Academic; 1988.

42. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. *BMC Med Res Methodol.* 2013;13(1). doi:10.1186/1471-2288-13-117

43. Sepucha KR, Borkhoff C, Lally J, Levin CA, Matlock D, et al. Establishing the effectiveness of patient decision aids: key constructs and measurement instruments. *BMC Med Inform Decis Mak.* 2013;13(Suppl 2).

44. Elwyn G, O’Connor A, Stacey D, et al. Developing a quality criteria framework for patient decision aids: Online international Delphi consensus process. *Br Med J.* 2006;333(7565):417–419. doi:10.1136/bmj.38926.629329.AE

45. Sepucha KR, Abhyankar P, Hoffman AS, et al. Standards for UNiversal reporting of patient Decision Aid Evaluation studies: the development of SUNDAE Checklist. *BMJ Qual Saf.* 2018;27(5):380–388. doi:10.1136/bmjqs-2017-006986

46. Rowlands G, Protheroe J, Winkley J, Richardson M, Seed PT, Rudd R. A mismatch between population health literacy and the complexity of health information: an observational study. *Br J Gen Pract.* 2015;65(635):e379 LP-e386. doi:10.3399/bjgp15X685285

47. Lung Screening in people cured of Hodgkin lymphoma. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04986189?term=lung+cancer&cond=hodgkin+lymphoma&draw=2&rank=2. Accessed August 19, 2021.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- supplementarydata.docx